Darah Protas

Cooley advised the underwriters in Karuna Therapeutics’ $862.5 million follow-on offering of 4,011,628 shares of common stock at a public offering price of $215 per share. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Partners Richard Segal, Jean Park, Div Gupta and associate Darah Protas led the Cooley team.

Cooley advised the underwriters in Verve Therapeutics’ $258.8 million follow-on offering of 9,583,334 shares of common stock at a public offering price of $27 per share. Verve is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene-editing medicines. Partners Rich Segal and Div Gupta, and associate Darah Protas, led the Cooley team.

Cooley advised the placement agents in Scholar Rock’s $205 million registered direct offering, with J.P. Morgan as lead placement agent and Piper Sandler as co-placement agent . Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Partners Daniel Goldberg, Div Gupta and Madison Jones led the Cooley team.

Cooley advised the underwriters on Apellis Pharmaceuticals’ $402.5 million follow-on offering of 8,563,830 shares of common stock at a price to the public of $47.00 per share. Apellis is a global biopharmaceutical company committed to leveraging courageous science, creativity and compassion to deliver life-changing therapies. Partners Div Gupta and Brent Siler led the Cooley team.

Cooley advised Meredith Corporation, a multiplatform media and marketing company, on its agreement to sell its National Media Group to IAC’s Dotdash. Partners Kevin Mills and Aaron Binstock led the Cooley team advising Meredith.